Drug intelligence / Profile preview

pembrolizumab + bevacizumab + FOLFIRI

Development stage: Preclinical
Lead developer: Merck
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

This combination involves **pembrolizumab**, a monoclonal antibody that acts as a checkpoint inhibitor targeting PD-1; **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF); and **FOLFIRI**, a chemotherapy regimen consisting of folinic acid, fluorouracil, and irinotecan. It is used in the treatment of metastatic colorectal cancer (mCRC).

Targets

TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)

Beyond the preview

Go deeper on pembrolizumab + bevacizumab + FOLFIRI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + bevacizumab + FOLFIRI.

Explore the full profile